ABACAVIR/LAMIVUDINE SUN (Sun Pharma ANZ Pty Ltd)
Product name
ABACAVIR/LAMIVUDINE SUN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
164 working days (255)
Active ingredients
Abacavir sulfate; Lamivudine
Registration type
New generic medicine
Indication
ABACAVIR/LAMIVUDINE (tablets) is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age.